Daxor (NASDAQ:DXR) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Daxor (NASDAQ:DXR) announced its quarterly earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07), FiscalAI reports. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $2.80 million.

Daxor Price Performance

Shares of Daxor stock traded down $0.30 during trading on Monday, hitting $9.90. 872 shares of the stock traded hands, compared to its average volume of 6,900. Daxor has a 52 week low of $8.56 and a 52 week high of $14.76. The firm’s fifty day moving average is $10.38 and its 200-day moving average is $10.56.

Institutional Trading of Daxor

A hedge fund recently bought a new position in Daxor stock. Osaic Holdings Inc. purchased a new stake in shares of Daxor Corporation (NASDAQ:DXR) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned about 0.18% of Daxor at the end of the most recent reporting period. Institutional investors own 1.34% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Daxor has an average rating of “Moderate Buy”.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA?100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA?100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.